What to do when morning stiffness keeps returning

What to notice when you first move

Brief stiffness often follows sleep, sitting, or repeated use. Arthritis can cause a deep ache inside the joint. A sore tendon usually hurts more during one repeated motion. Warmth or swelling gives the examiner another fact to check.

Record how many minutes pass before movement feels easier. Note the task that makes the joint hurt again. You aren't expected to name the cause yourself. They'll use those details to choose what to examine.

What to try while the joint settles

Begin with easy motion and shorter periods of activity. Don't force a movement that gives you a sharp jab. Supportive shoes can ease some load on the legs. A pillow can hold a sore shoulder in a calmer position.

If the soreness keeps coming back, QC Kinetix can examine the joint. Its medical providers are the health care staff who review your health and earlier care. Biologic therapy means they draw your blood, prepare part of it there, and place that part at the sore area. This non-surgical option aims to calm the ache and make movement easier.

When to ask for a closer look

Arrange an exam once dressing, walking, or sleep gets harder. Tell the provider exactly which movement stops you. Bring reports from earlier visits and any old X-ray. Your medicine list also belongs in your bag.

The exam comes before any treatment choice. The provider checks movement, swelling, strength, and tender spots. Natural pain treatments means care made from your own blood instead of a manufactured drug. Ordinary care can include exercise, heat, cold, or medicine from your doctor.

Sources

1. The AAOS third-edition clinical practice guideline on non-arthroplasty management of knee osteoarthritis contains 29 recommendations and explicitly highlights intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as the areas where better research is still needed - including osteoarthritis characterisation, subgroup and severity stratification, control for bias, and cost-effectiveness analysis.

   Brophy RH, Fillingham YA. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

4. A JBJS systematic review screened 420 papers on intra-articular cellular therapy for knee OA and focal cartilage defects and found only SIX studies at Level III evidence or higher, covering 300 knees, with wide variation in cell source, cell characterisation, adjuvant therapy and outcome assessment. All six reported improvement and no major adverse events, but the authors concluded the improvement was modest, a placebo effect could not be disregarded, and no consensus exists on indications, cell sources, preparation or delivery.

   Chahla J, Piuzzi NS, et al. — Intra-Articular Cellular Therapy for Osteoarthritis and Focal Cartilage Defects of the Knee: A Systematic Review of the Literature and Study Quality Analysis.. Journal of Bone and Joint Surgery (American), 2016. DOI: 10.2106/JBJS.15.01495.

5. A fragility-index analysis of the RCTs underpinning PRP for knee OA (1,993 patients) found the mean number of outcome events needed to reverse an individual trial's statistical significance was only 4.57, and 8.67 for the pooled meta-analytic effects. On meta-analysis PRP did show an advantage over hyaluronic acid (OR 2.19) and higher rates of achieving the MCID for pain versus alternatives (OR 6.19) - but the conclusions rest on a small number of events, which is the technical way of saying the literature is not robust.

   Oeding JF, et al. — Platelet-Rich Plasma Versus Alternative Injections for Osteoarthritis of the Knee: A Systematic Review and Statistical Fragility Index-Based Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465231224463.

6. A systematic mapping of the entire injectable knee OA literature since 1959 identified 766 clinical studies covering 75,834 patients: 11,245 treated with corticosteroid, 40,862 with hyaluronic acid, 16,174 with PRP and 7,553 with cell-based therapies. Hyaluronic acid still has the largest evidence base; PRP has recently overtaken corticosteroid in number of studies; placebo-controlled RCTs remain limited and only a negligible percentage of studies examined disease-modifying effects.

   Bensa A, et al. — Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments' evidence: a systematic review and expert opinion.. Expert Opinion on Biological Therapy, 2025. DOI: 10.1080/14712598.2025.2465833.